相关实验视频

Updated: Jan 10, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

如何冷磨粉和冷化影响固体散布与Etodolac的属性?

Anna Czajkowska-Kośnik¹, Radosław A Wach², Eliza Wolska³

¹Department of Pharmaceutical Technology, Medical University of Białystok, Mickiewicza 2c, 15-222 Białystok, Poland.

|November 27, 2025

概括

埃托多拉克 (ETD) 的固体分散 (SD) 使用聚乙烯酸-聚乙烯酸 (PVP/VA) 和波洛克萨默 (poloxamer) 共聚合物被开发出来. 解热化产生了最佳的配方,提高了ETD的溶解性和溶解性,同时降低了结晶性.

科学领域:

制药科学制药科学
材料科学材料科学材料科学

背景情况:

埃托多拉克 (ETD) 是一种水溶性较差的非类固醇抗炎药物.
提高ETD的可溶性和溶解率对于改善其生物可用性至关重要.
固体分散 (SDs) 提供了一种有希望的方法来克服这些挑战.

研究的目的:

开发和描述埃托多拉克 (ETD) 的固体分散 (SD).
研究各种水友性/两友性聚合物和制备方法对ETD溶解性和溶解性的影响.
确定一个优化的SD配方,以增强药物输送.

主要方法:

通过冷磨粉和冷化技术制备了固体分散剂.
使用的聚合物包括聚烯罗立-聚乙酸乙烯聚合物 (PVP/VA),基甲基纤维素 (HPMC) 和poloxamer.
描述涉及药物含量,可溶性,溶解率,水分含量,SEM,DSC和FTIR分析.

主要成果:

所有SD配方都显示在水性介质和缓冲中增强了ETD溶解性.
用PVP/VA和poloxamer配制的SDs表现出改善的溶解和减少的再结晶,这得到了DSC的证实.
FTIR分析表明,ETD与聚合物之间形成键,特别是在冷分散物中.

结论:

使用PVP/VA和/或poloxamer作为载体的冷化导致了优化的ETD固体分散.
优化的SD配方显著提高了ETD的溶解性和溶解率.
这种配方有效地降低了药物的结晶性,为改善治疗疗效铺平了道路.

关键词:

美国国家安全委员会 DSC.美国的FTIR是FTIR.结冷磨的方法药物溶解度药物溶解度药物溶解度这里是Etodolac的地方.溶解化的方法固体分散的固体分散

更多相关视频

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Published on: March 3, 2020

相关概念视频

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

In Vitro Drug Dissolution: Alternative Methods

In Vitro Drug Dissolution: Alternative Methods

Alternative drug dissolution methods include the rotating bottle, intrinsic dissolution test, peristalsis, and the Franz diffusion cell method. The rotating bottle method involves meticulously rotating tightly capped controlled-release beads in a temperature-controlled bath. Periodic decanting of samples allows for residue assay, followed by refilling with fresh medium and testing at various pH levels to emulate the gastrointestinal tract conditions.In contrast, the intrinsic dissolution test...